GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                               
                            
                                
                                                                Synonyms: Azstarys® (serdexmethylphenidate + dexmethylphenidate) | KP-484 | KP484
                                 
                                                         
                            
                            
                            
                                 
                                
                                serdexmethylphenidate is an approved drug (FDA (2021)) 
                                                        
                                                    
                                Compound class: 
                                                            Synthetic organic
                                 
                                
                                    
                                        Comment: Serdexmethylphenidate (KP484) is a prodrug that is a slow-release derivative of dexmethylphenidate (d-MPH).
                                    
                                 
                            
                            
                          
                                
                                    
                                
                          
                                   
                                   
                                  
                                    
                                    
                                     | 
                                    
                                        
                                         
  | 
                                    
                                
                                |||||||||||||||||||||||||||||||||||
| Bioactivity Comments | 
| We have been unable to find published activity data for this compiund at any molecular target. It is likely to act via inhibition of the dopamine and norepinephrine transporters (DAT), like dexmethylphenidate, and thus reduce catecholamine reuptake at the synapse. |